Albany Molecular Research (Albany Molecular Research) Total Current Assets : $403.9 Mil (As of Jun. 2017)

View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Albany Molecular Research's total current assets for the quarter that ended in Jun. 2017 was $403.9 Mil.

Albany Molecular Research Total Current Assets Historical Data

The historical data trend for Albany Molecular Research's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research Total Current Assets Chart

Albany Molecular Research Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Current Assets

Get a 7-Day Free Trial

113.42

279.02

188.54

280.25

392.91

Albany Molecular Research Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
Total Current Assets	Get a 7-Day Free Trial															256.65	404.25	392.91	385.15	403.91

Albany Molecular Research Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Albany Molecular Research's Total Current Assets for the fiscal year that ended in Dec. 2016 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	52	+	150.307	+	167.111	+	23.493
	=	392.9

Albany Molecular Research's Total Current Assets for the quarter that ended in Jun. 2017 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	42.227	+	147.629	+	186.409	+	27.647
	=	403.9

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Albany Molecular Research (NAS:AMRI) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Albany Molecular Research's Liquidation Value for the quarter that ended in Jun. 2017 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	42.227	-	925.351	+	0.75 * 139.342	+	0.5 * 186.409
=	-685.4

Albany Molecular Research Total Current Assets Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Albany Molecular Research (Albany Molecular Research) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.amriglobal.com

Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.

Executives

Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin	officer: SVP, Treasurer & CFO	26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming	director	C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth	director, officer: President and CEO	236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson	officer: SVP, Secretary & Gen Counsel	MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan	director	329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung	director	C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther	officer: Senior VP, Discovery Services	21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost	officer: Chief Financial Officer	21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek	officer: Chief Financial Officer	ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines